Bristol Myers Squibb Company may have entered a new era under new CEO Christopher Boerner, who took the helm from retiring CEO Giovanni Caforio in November – an era in which the company more aggressively looks to fill gaps in its portfolio through mergers and acquisitions. Bristol announced on 26 December that it would pay $4.1bn for RayzeBio, Inc., just four days after BMS said it would buy Karuna Therapeutics, Inc. for $14bn.
BMS Makes Second Big Buy Of December, Pays $4.1bn For RayzeBio
Bristol Myers Squibb makes its entrance into the increasingly competitive space of radiopharmaceuticals with its latest purchase, just days after its $14bn Karuna buy.
More from Deals
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.